How Smart Motorcycles are Adapting to a Post-Pandemic Market

 

COVID-19 has disrupted just about every aspect of business, including supply chains. As manufacturers scramble to adapt, Damon Motorcycles, a manufacturer of technology-enabled, electric motorcycles, has been able to keep producing products, which the CEO Jay Giraud discusses on today’s MarketScale Live

Supply chains in the vehicle manufacturing field have impacted many, but Damon Motorcycles has been able to weather the storm well, due to manufacturing in country and a simpler design than most motorcycle manufacturers.

Jay said, “We’re a Canadian company that manufactures here with the majority of components and assembly within the country. With an electric motor, it’s only a few parts and a simple supply chain. Gas engines require many more parts, creating a very complex supply chain.”

The company has actually seen a 60 percent growth since the pandemic started. They attribute this to a change in their buyer, which are mainly millennials. This generation puts much focus on safety, technology, and authenticity, three things Damon Motorcycles exemplifies.

“The landscape of life has changed, and people want freedom of mobility,” Jay shared. That mobility doesn’t always equate to a car or mass transportation. Jay stated, “Most cities don’t have the subway system of New York or London, and drivers in large metro areas spend about one-third of their driving time looking for a parking space. This isn’t sustainable.”

Motorcycles have an opportunity to fit this need but in a modern way. Innovation and a new approach to motorcycles helped the company win some major awards, including two from CES 2020

Watch more of the interview with Jay to learn more about Damon Motorcycles and the future of mobility. 

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More